COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
No abstract available

Publication types

  • Video-Audio Media

MeSH terms

  • Angiotensin Receptor Antagonists / adverse effects*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Antihypertensive Agents / adverse effects*
  • Antihypertensive Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Lung Injury / drug therapy
  • Lung Injury / enzymology
  • Mice
  • Pandemics
  • Peptidyl-Dipeptidase A / drug effects
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology
  • SARS Virus / pathogenicity
  • SARS-CoV-2
  • Vasodilation / physiology
  • Virus Internalization

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2